Borderline personality disorder (BPD) is a serious chronic condition which may lead to a poor quality of life and carries a considerable risk of comorbidity and suicide. The syndrome has been acknowledged and investigated in psychiatry for at least seventy years. The DSM-IV gives a panel of nine symptoms and manifestations for its diagnosis, but not taking into account neurobiological and objective issues.
neurologic signs would aid to better characterize BPD patients for further research and effective treatments.
Although BPD and major depression (MD) can coexist, the depressive state most frequently associated with BPD seems to be distinct from nonborderline depression in terms of quality and duration of symptoms. Emptiness, loneliness, labile affect, behavioral dysregulation, anger and tension, self-condemnation, abandonment fears, self-destructiveness and hopelessness appear to be specifi c clusters of borderline affective symptoms (Rogers et al., 1995) .These symptoms typically last between two and four days and reappear several times a month. Pharmacological studies have shown differences in treatment response between BPD and MD, conventional antidepressants and ECT have exhibited poor response (Feske et al., 2004) and even worsening in BPD.
Diverse laboratory data registered in the last few years have guided to propose that the depressive symptoms in BPD have a distinct biological substrate than those in the nonborderline depressive illness (De la Fuente et al., 2002; . Recent receptor studies have found the hippocampal 5HT(2A) receptor binding, which is decreased in MD (Mintun et al., 2004) , is increased in BPD with binding values being related to comorbid MD but not to depressed mood (Soloff et al., 2007) .
Recurrent brief depression (RBD) has been proposed to overlap with BPD but RBD has been found to share perturbed biological substrates (endocrine and sleep-EEG) with MD (Staner et al., 1992) whereas others (De la Fuente et al., 2002; have not found this pathological shared substrate in BPD. From a biological point of view, this seems to distance BPD from RBD.
We suggest that a new subcategory be included in the DSM-V criteria sets for further study, which could be named 'BPD-related affective disorder' characterized by depressive symptoms of a distinct quality than in MD, a brief duration of the episodes, less than two weeks, and by a biological substrate different from those found in MD. BPD patients without concomitant MD have not shown abnormality in endocrine tests (De la Fuente et al., 2002) . In the subcategory proposed, the hypothalamic pituitary axis would probably not be altered, or at least not in the same way than in MD. The same would be true for the sleep-EEG.
The existence of this new subcategory in a structured framework as the DSM-V would aid to replicate, or not, previous results with larger samples and it would make it possible to perform homogeneous neurotransmission, molecular, genetic, nosology and epidemiological research. This would also allow testing new molecules in uniform BPD-affective and non-affective samples and in fi ne to reduce the enormous burden that BPD produces, not only in terms of suicide and impulsivity-related mortality but also in terms of quality of life.
